Weighed down by the cost of opioid litigation, the American Pain Society is considering filing for bankruptcy and a decision is expected next week.

In a May 20 letter to its members, the APS board of directors blamed financial problems that have been exacerbated by the mounting expenses associated with defending lawsuits filed by local, city, and state governments over the opioid crisis. Along with drug makers and wholesalers, the professional society was named as a defendant in many of the cases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy